Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 11:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 3,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Clear all
Completed Phase 2 Interventional

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

NCT00096499
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ispinesib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Nov 1, 2026, 11:22 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Defining Recurrent Disease With Axumin™

NCT03996993
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Casodex, Axumin, Salvage Radiation, Axumin
Drug · Radiation
Lead sponsor
Cancer Center of Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
44
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Not listed Phase 3 Interventional

I-125 Versus Pd-103 for Medium Risk Prostate Cancer

NCT00486499
View directory record Official record
Conditions
Prostate Cancer
Interventions
I-125 versus Pd-103 radioactive seed insertion
Procedure
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
40 Years to 90 Years · Male only
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2007 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting Phase 3 Interventional

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398
View directory record Official record
Conditions
Metastatic Castrate-sensitive Prostate Cancer
Interventions
Apalutamide, Androgen-deprivation Therapy (ADT)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting Phase 1 Interventional

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

NCT07517198
View directory record Official record
Conditions
Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions
EXS74539
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Fort Worth, Texas • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed No phase listed Observational

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

NCT03535987
View directory record Official record
Conditions
Prostate Cancer
Interventions
myocardial PET imaging
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
51 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting No phase listed Observational

Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI

NCT04992728
View directory record Official record
Conditions
Prostate Cancer
Interventions
Restricted Spectrum Magnetic Resonance Imagining
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting Not applicable Interventional

3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer

NCT01653093
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-Tesla magnetic resonance imaging (3T MRI), diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopic imaging
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
Male only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Completed No phase listed Observational

Application of Megavoltage Imaging to Reduce Artifact After Seed Implants

NCT01810627
View directory record Official record
Conditions
Prostate Cancer
Interventions
MVCT
Radiation
Lead sponsor
William St Clair
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Nov 1, 2026, 11:22 AM EST
Not yet recruiting Early Phase 1 Interventional

Preoperative Semaglutide Prior to Radical Prostatectomy

NCT07727473
View directory record Official record
Conditions
Prostate Cancer
Interventions
Semaglutide 2.4 mg
Drug
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Phase 1 Interventional

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

NCT00002677
View directory record Official record
Conditions
Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
chemotherapy, tributyrin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Nov 1, 2026, 11:22 AM EST
Suspended Not applicable Interventional

Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy

NCT04646434
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Electroencephalography, Electromyography, Questionnaire Administration, Urodynamics (UDS)
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed No phase listed Observational

Prospective Evaluation of a Commercially Available Hydrogel Spacer

NCT05323747
View directory record Official record
Conditions
Prostate Cancer
Interventions
Observation
Other
Lead sponsor
BioProtect
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Campbell, California • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Suspended Phase 1 Interventional

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

NCT00909558
View directory record Official record
Conditions
Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer, Prostate Cancer
Interventions
Autologous Natural Killer / Natural Killer T Cell Immunotherapy
Biological
Lead sponsor
Envita Medical Center, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Nov 1, 2026, 11:22 AM EST
Terminated Phase 1 Interventional

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
Interventions
P-PSMA-101 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Duarte, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Nov 1, 2026, 11:22 AM EST
Recruiting Phase 1 Interventional

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

NCT07090148
View directory record Official record
Conditions
Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
Interventions
pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Not listed Phase 2 Interventional

Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer

NCT00732043
View directory record Official record
Conditions
Prostate Cancer
Interventions
pomegranate extract, pomegranate juice, placebo
Dietary Supplement
Lead sponsor
Roll International Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Nov 1, 2026, 11:22 AM EST
Completed Not applicable Interventional

Early Staged Consent Before Prostate Biopsy

NCT03507725
View directory record Official record
Conditions
Prostate Cancer
Interventions
Meditation, Prostate Biopsy, Questionnaires
Behavioral · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Nov 1, 2026, 11:22 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer

NCT06326216
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Completed Not applicable Interventional Results available

Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study

NCT04870515
View directory record Official record
Conditions
Localized Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Best Practice, Dietary Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Nov 1, 2026, 11:22 AM EST
Terminated Phase 2 Interventional

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

NCT00450008
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, thalidomide, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Nov 1, 2026, 11:22 AM EST
Terminated Phase 2 Interventional Results available

Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer

NCT00678015
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nordihydroguaiaretic Acid (NDGA)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Nov 1, 2026, 11:22 AM EST
Not listed Phase 2Phase 3 Interventional

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

NCT00043576
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, docetaxel
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
52
States / cities
Montgomery, Alabama • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Nov 1, 2026, 11:22 AM EST